Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.
Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.
Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.
Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.
Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.
Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.
Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured by the media, academic trade publications & journals.
Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured by the media, academic trade publications & journals.
Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured by the media, academic trade publications & journals.
Here are some of the Duke Cancer Institute faculty, researchers, and clinical providers whose work has recently been featured by the media, academic trade publications & journals.
Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured by the media, academic trade publications & journals.
Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured by the media, academic trade publications & journals.
Astellas Pharma Inc. announced on May 4 that the European Commission has approved enzalutamide for adult men with metastatic hormone-sensitive prostate cancer.
Various genetic alterations in circulating tumor cells were associated with clinical outcomes and resistance to hormone therapy in patients with mCRPC.
DCI pathologist Jung Wook Park, PhD, mentored by Jiaoti Huang, MD, PhD, and Andrew Armstrong, MD, MSc, has received a Prostate Cancer Foundation Young Investigator Award.
Here are some of the DCI physicians, physician-scientists, researchers & nurses whose work has recently been featured by the media, academic trade publications & journals.
Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.
Duke Cancer Institute will present more than 100 abstracts across multiple cancer types during the ASCO20 Virtual Scientific Program of the 2020 ASCO Annual Meeting.
Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.
Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.
Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.
Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.
Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.
Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.
Andrew Armstrong, MD, found that treatment with enzalutamide and ADT significantly reduced the risk of metastasis or death over time in men with mHSPC.
Some of the newest and most exciting cancer treatments don’t work for everybody. Instead, they target tumors that have a specific genetic mutation or characteristic.
Here's a sample of some of the DCI physicians, physician-scientists, researchers and nurses whose work is featured by the media and in academic journals.